Author: "Matthews, Gail V / Search Limiters: Peer Reviewed - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Matthews, Gail V ' showing total 303 results

Start Over Author "Matthews, Gail V Search Limiters Peer Reviewed

303 results on '"Matthews, Gail V '

1. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection

Author: Phetsouphanh, Chansavath, Jacka, Brendan, Ballouz, Sara, Jackson, Katherine J. L., Wilson, Daniel B., Manandhar, Bikash, Klemm, Vera, Tan, Hyon-Xhi, Wheatley, Adam, Aggarwal, Anupriya, Akerman, Anouschka, Milogiannakis, Vanessa, Starr, Mitchell, Cunningham, Phillip, Turville, Stuart G., Kent, Stephen J., Byrne, Anthony, Brew, Bruce J., Darley, David R., Dore, Gregory J., Kelleher, Anthony D., and Matthews, Gail V.
Published: 2024
Full Text: View/download PDF

2. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

Author: Astrid Marchal, Elizabeth T. Cirulli, Iva Neveux, Evangelos Bellos, Ryan S. Thwaites, Kelly M. Schiabor Barrett, Yu Zhang, Ivana Nemes-Bokun, Mariya Kalinova, Andrew Catchpole, Stuart G. Tangye, András N. Spaan, Justin B. Lack, Jade Ghosn, Charles Burdet, Guy Gorochov, Florence Tubach, Pierre Hausfater, Clifton L. Dalgard, Shen-Ying Zhang, Qian Zhang, Christopher Chiu, Jacques Fellay, Joseph J. Grzymski, Vanessa Sancho-Shimizu, Laurent Abel, Jean-Laurent Casanova, Aurélie Cobat, Alexandre Bolze, Alessandro Aiuti, Saleh Al-Muhsen, Fahd Al-Mulla, Ali Amara, Mark S. Anderson, Evangelos Andreakos, Andrés A. Arias, Lisa M. Arkin, Hagit Baris Feldman, Paul Bastard, Alexandre Belot, Catherine M. Biggs, Dusan Bogunovic, Anastasiia Bondarenko, Alessandro Borghesi, Ahmed A. Bousfiha, Petter Brodin, Yenan Bryceson, Manish J. Butte, Giorgio Casari, John Christodoulou, Roger Colobran, Antonio Condino-Neto, Stefan N. Constantinescu, Megan A. Cooper, Murkesh Desai, Beth A. Drolet, Xavier Duval, Jamila El Baghdadi, Philippine Eloy, Sara Espinosa-Padilla, Carlos Flores, José Luis Franco, Antoine Froidure, Peter K. Gregersen, Bodo Grimbacher, Filomeen Haerynck, David Hagin, Rabih Halwani, Lennart Hammarström, James R. Heath, Elena W.Y. Hsieh, Eystein Husebye, Kohsuke Imai, Yuval Itan, Emmanuelle Jouanguy, Elżbieta Kaja, Timokratis Karamitros, Kai Kisand, Cheng-Lung Ku, Yu-Lung Lau, Yun Ling, Carrie L. Lucas, Tom Maniatis, Davood Mansouri, László Maródi, France Mentré, Isabelle Meyts, Joshua D. Milner, Kristina Mironska, Trine H. Mogensen, Tomohiro Morio, Lisa F.P. Ng, Luigi D. Notarangelo, Antonio Novelli, Giuseppe Novelli, Cliona O'Farrelly, Satoshi Okada, Keisuke Okamoto, Tayfun Ozcelik, Qiang Pan-Hammarström, Jean W. Pape, Rebeca Perez de Diego, Jordi Perez-Tur, David S. Perlin, Graziano Pesole, Anna M. Planas, Carolina Prando, Aurora Pujol, Anne Puel, Lluis Quintana-Murci, Sathishkumar Ramaswamy, Laurent Renia, Igor Resnick, Carlos Rodríguez-Gallego, Anna Sediva, Mikko R.J. Seppänen, Mohammad Shahrooei, Anna Shcherbina, Ondrej Slaby, Andrew L. Snow, Pere Soler-Palacín, Vassili Soumelis, Ivan Tancevski, Ahmad Abou Tayoun, Şehime Gülsün Temel, Christian Thorball, Pierre Tiberghien, Sophie Trouillet-Assant, Stuart E. Turvey, K. M. Furkan Uddin, Mohammed J. Uddin, Diederik van de Beek, Donald C. Vinh, Horst von Bernuth, Joost Wauters, Mayana Zatz, Pawel Zawadzki, Serge Bureau, Yannick Vacher, Anne Gysembergh-Houal, Lauren Demerville, Abla Benleulmi-Chaachoua, Sebastien Abad, Radhiya Abassi, Abdelrafie Abdellaoui, Abdelkrim Abdelmalek, Hendy Abdoul, Helene Abergel, Fariza Abeud, Sophie Abgrall, Noemie Abisror, Marylise Adechian, Nordine Aderdour, Hakeem Farid Admane, Frederic Adnet, Sara Afritt, Helene Agostini, Claire Aguilar, Sophie Agut, Tommaso Francesco Aiello, Marc Ait Kaci, Hafid Ait Oufella, Gokula Ajeenthiravasan, Virginie Alauzy, Fanny Alby-Laurent, Lucie Allard, Marie-Alexandra Alyanakian, Blanca Amador Borrero, Sabrina Amam, Lucile Amrouche, Marc Andronikof, Dany Anglicheau, Nadia Anguel, Djillali Annane, Mohammed Aounzou, Caroline Aparicio, Gladys Aratus, Jean-Benoit Arlet, Jeremy Arzoine, Elisabeth Aslangul, Mona Assefi, Adeline Aubry, Laetitia Audiffred, Etienne Audureau, Christelle Nathalie Auger, Jean-Charles Auregan, Celine Awotar, Sonia Ayllon Milla, Delphine Azan, Laurene Azemar, Billal Azzouguen, Marwa Bachir Elrufaai, Aïda Badsi, Prissile Bakouboula, Coline Balcerowiak, Fanta Balde, Elodie Baldivia, Eliane-Flore Bangamingo, Amandine Baptiste, Fanny Baran-Marszak, Caroline Barau, Nathalie Barget, Flore Baronnet, Romain Barthelemy, Jean-Luc Baudel, Camille Baudry, Elodie Baudry, Laurent Beaugerie, Adel Belamri, Nicolas Belaube, Rhida Belilita, Pierre Bellassen, Rawan Belmokhtar, Isabel Beltran, Ruben Benainous, Mourad Benallaoua, Robert Benamouzig, Amélie Benbara, Jaouad Benhida, Anis Benkhelouf, Jihene Benlagha, Chahinez Benmostafa, Skander Benothmane, Miassa Bentifraouine, Laurence Berard, Quentin Bernier, Enora Berti, Astrid Bertier, Laure Berton, Simon Bessis, Alexandra Beurton, Celine Bianco, Clara Bianquis, Frank Bidar, Philippe Blanche, Clarisse Blayau, Alexandre Bleibtreu, Emmanuelle Blin, Coralie Bloch-Queyrat, Marie-Christophe Boissier, Diane Bollens, Marion Bolzoni, Rudy pierre Bompard, Nicolas Bonnet, Justine Bonnouvrier, Shirmonecrystal Botha, Wissam Boucenna, Fatiha Bouchama, Olivier Bouchaud, Hanane Bouchghoul, Taoueslylia Boudjebla, Noel Boudjema, Catherine Bouffard, Adrien Bougle, Meriem Bouguerra, Leila Bouras, Agnes Bourcier, Anne Bourgarit Durand, Anne Bourrier, Fabrice Bouscarat, Diane Bouvry, Nesrine Bouziri, Ons Bouzrara, Sarah Bribier, Delphine Brugier, Melanie Brunel, Eida Bui, Anne Buisson, Iryna Bukreyeva, Côme Bureau, Jacques Cadranel, Johann Cailhol, Ruxandra Calin, Clara Campos Vega, Pauline Canavaggio, Marta Cancella, Delphine Cantin, Albert Cao, Lionel Carbillon, Nicolas Carlier, Clementine Cassard, Guylaine Castor, Marion Cauchy, Olivier Cha, Benjamin Chaigne, Salima Challal, Karine Champion, Patrick Chariot, Julie Chas, Simon Chauveau, Anthony Chauvin, Clement Chauvin, Nathalie Chavarot, Kamélia Chebbout, Mustapha Cherai, Ilaria Cherubini, Amelie Chevalier, Thibault Chiarabini, Thierry Chinet, Richard Chocron, Pascaline Choinier, Juliette Chommeloux, Christophe Choquet, Laure Choupeaux, Benjamin Chousterman, Dragosmarius Ciocan, Ada Clarke, Gaëlle Clavere, Florian Clavier, Karine Clement, Sebastien Clerc, Yves Cohen, Fleur Cohen, Adrien Cohen, Audrey Coilly, Hester Colboc, Pauline Colin, Magalie Collet, Chloé Comarmond, Emeline Combacon, Alain Combes, Celine Comparon, Jean-Michel Constantin, Hugues Cordel, Anne-Gael Cordier, Adrien Costantini, Nathalie Costedoat Chalumeau, Camille Couffignal, Doriane Coupeau, Alain Creange, Yannie Cuvillier Lamarre, Charlène Da Silveira, Sandrine Dautheville Guibal El Kayani, Nathalie De Castro, Yann De Rycke, Lucie Del Pozo, Quentin Delannoy, Mathieu Delay, Robin Deleris, Juliette Delforge, Laëtitia Delphine, Noemie Demare, Sophie Demeret, Alexandre Demoule, Aurore Deniau, François Depret, Sophie Derolez, Ouda Derradji, Nawal Derridj, Vincent Descamps, Lydia Deschamps, Celine Desconclois, Cyrielle Desnos, Karine Desongins, Robin Dhote, Benjamin Diallo, Morgane Didier, Myriam Diemer, Stephane Diez, Juliette Djadi-Prat, Fatima-Zohra Djamouri Monnory, Siham Djebara, Naoual Djebra, Minette Djietcheu, Hadjer Djillali, Nouara Djouadi, Severine Donneger, Catarina Dos Santos, Nathalie Dournon, Martin Dres, Laura Droctove, Marie Drogrey, Margot Dropy, Elodie Drouet, Valérie Dubosq, Evelyne Dubreucq, Estelle Dubus, Boris Duchemann, Thibault Duchenoy, Emmanuel Dudoignon, Romain Dufau, Florence Dumas, Clara Duran, Emmanuelle Duron, Antoine Durrbach, Claudine Duvivier, Nathan Ebstein, Jihane El Khalifa, Alexandre Elabbadi, Caroline Elie, Gabriel Ernotte, Anne Esling, Martin Etienne, Xavier Eyer, Muriel Sarah Fartoukh, Takoua Fayali, Marion Fermaut, Arianna Fiorentino, Souha Fliss, Marie-Céline Fournier, Benjamin Fournier, Hélène Francois, Olivia Freynet, Yvann Frigout, Isaure Fromont, Axelle Fuentes, Thomas Furet, Joris Galand, Marc Garnier, Agnes Gaubert, Stéphane Gaudry, Samuel Gaugain, Damien Gauthier, Maxime Gautier, Sophie Georgin-Lavialle, Daniela Geromin, Mohamed Ghalayini, Bijan Ghaleh, Myriam Ghezal, Aude Gibelin, Linda Gimeno, Benoit Girard, Bénédicte Giroux Leprieur, Doryan Gomes, Elisabete Gomes-Pires, Anne Gouge, Amel Gouja, Helene Goulet, Sylvain Goupil, Jeanne Goupil De Bouille, Julien Gras, Segolene Greffe, Lamiae Grimaldi, Paul Guedeney, Bertrand Guidet, Matthias Guillo, Mariechristelle Gulczynski, Tassadit Hadjam, Didier Haguenauer, Soumeya Hammal, Nadjib Hammoudi, Olivier Hanon, Anarole Harrois, Coraline Hautem, Guillaume Hekimian, Nicholas Heming, Olivier Hermine, Sylvie Ho, Marie Houllier, Benjamin Huot, Tessa Huscenot, Wafa Ibn Saied, Ghilas Ikherbane, Meriem Imarazene, Patrick Ingiliz, Lina Iratni, Stephane Jaureguiberry, Jean-Francois Jean-Marc, Deleena Jeyarajasingham, Pauline Jouany, Veronique Jouis, Clement Jourdaine, Ouifiya Kafif, Rim Kallala, Sandrine Katsahian, Lilit Kelesyan, Vixra Keo, Flora Ketz, Warda Khamis, Enfel Khelili, Mehdi Khellaf, Christy Gaëlla Kotokpo Youkou, Ilias Kounis, Gaelle Kpalma, Jessica Krause, Vincent Labbe, Karine Lacombe, Jean-Marc Lacorte, Anne Gaelle Lafont, Emmanuel Lafont, Lynda Lagha, Lionel Lamhaut, Aymeric Lancelot, Cecilia Landman, Fanny Lanternier, Cecile Larcheveque, Caroline Lascoux Combe, Ludovic Lassel, Benjamin Laverdant, Christophe Lavergne, Jean-Rémi Lavillegrand, Pompilia Lazureanu, Loïc Le Guennec, Lamia Leberre, Claire Leblanc, Marion Leboyer, Francois Lecomte, Marine Lecorre, Romain Leenhardt, Marylou Lefebvre, Bénédicte Lefebvre, Paul Legendre, Anne Leger, Laurence Legros, Justyna Legrosse, Sébastien Lehuunghia, Julien Lemarec, Jeremie Leporrier-Ext, Manon Lesein, Hubert Lesur, Vincent Levy, Albert Levy, Edwige Lopes, Amanda Lopes, Vanessa Lopez, Julien Lopinto, Olivier Lortholary, Badr Louadah, Bénédicte Loze, Marie-Laure Lucas, Axelle Lucasamichi, Liem Binh Luong, Arouna Magazimama-Ext, David Maingret, Lakhdar Mameri, Philippe Manivet, Cylia Mansouri, Estelle Marcault, Jonathan Marey, Nathalie Marin, Clémence Marois, Olivier Martin, Lou Martineau, Cannelle Martinez-Lopez, Pierre Martyniuck, Pauline Mary De Farcy, Nessrine Marzouk, Rafik Masmoudi, Alexandre Mebazaa, Frédéric Mechai, Fabio Mecozzi, Chamseddine Mediouni, Bruno Megarbane, Mohamed Meghadecha, Élodie Mejean, Arsene Mekinian, Nour Mekki Abdelhadi, Rania Mekni, Thinhinan Sabrina Meliti, Breno Melo Lima, Paris Meng, Soraya Merbah, Fadhila Messani, Yasmine Messaoudi, Baboo-Irwinsingh Mewasing, Lydia Meziane, Carole Michelot-Burger, Françoise Mignot, Fadi Hillary Minka, Makoto Miyara, Pierre Moine, Jean-Michel Molina, Anaïs Montegnies-Boulet, Alexandra Monti, Claire Montlahuc, Anne-Lise Montout, Alexandre Moores, Caroline Morbieu, Helene Mortelette, Stéphane Mouly, Rosita Muzaffar, Cherifa Iness Nacerddine, Marine Nadal, Hajer Nadif, Kladoum Nassarmadji, Pierre Natella, Sandrine Ndingamondze, Stefan Neraal, Caroline Nguyen, Bao N'Guyen, Isabelle Nion Larmurier, Luc Nlomenyengue, Nicolas Noel, Hilario Nunes, Edris Omar, Zineb Ouazene, Elise Ouedraogo, Wassila Ouelaa, Anissa Oukhedouma, Yasmina Ould Amara, Herve Oya, Johanna Oziel, Thomas Padilla, Elena Paillaud, Solenne Paiva, Beatrice Parfait, Perrine Parize, Christophe Parizot, Antoine Parrot, Arthur Pavot, Laetitia Peaudecerf, Frédéric Pene, Marion Pepin, Julie Pernet, Claire Pernin, Mylène Petit, Olivier Peyrony, Marie-Pierre Pietri, Olivia Pietri, Marc Pineton De Chambrun, Michelle Pinson, Claire Pintado, Valentine Piquard, Christine Pires, Benjamin Planquette, Sandrine Poirier, Anne-Laure Pomel, Stéphanie Pons, Diane Ponscarme, Annegaelle Pourcelot, Valérie Pourcher, Anne Pouvaret, Florian Prever, Miresta Previlon, Margot Prevost, Marie-Julie Provoost, Cyril Quemeneur, Cédric Rafat, Agathe Rami, Brigitte Ranque, Maurice Raphael, Jean Herle Raphalen, Anna Rastoin, Mathieu Raux, Amani Rebai, Michael Reby, Alexis Regent, Asma Regrag, Matthieu Resche-Rigon, Quentin Ressaire, Christian Richard, Mariecaroline Richard, Maxence Robert, Benjamin Rohaut, Camille Rolland-Debord, Jacques Ropers, Anne-Marie Roque-Afonso, Charlotte Rosso, Mélanie Rousseaux, Nabila Rousseaux, Swasti Roux, Lorène Roux, Claire Rouzaud, Antoine Rozes, Emma Rubenstein, Jean-Marc Sabate, Sheila Sabet, Sophie-Caroline Sacleux, Nathalie Saidenberg Kermanach, Faouzi Saliba, Dominique Salmon, Laurent Savale, Guillaume Savary, Rebecca Sberro, Anne Scemla, Frederic Schlemmer, Mathieu Schwartz, Saïd Sedfi, Samia Sefir-Kribel, Philippe Seksik, Pierre Sellier, Agathe Selves, Nicole Sembach, Luca Semerano, Marie-Victoire Senat, Damien Sene, Alexandra Serris, Lucile Sese, Naima Sghiouar, Johanna Sigaux, Martin Siguier, Johanne Silvain, Noémie Simon, Tabassome Simon, Lina Innes Skandri, Miassa Slimani, Aurélie Snauwaert, Harry Sokol, Heithem Soliman, Nisrine Soltani, Benjamin Soyer, Gabriel Steg, Lydia Suarez, Tali-Anne Szwebel, Kossi Taffame, Yacine Tandjaoui-Lambiotte, Claire Tantet, Mariagrazia Tateo, Igor Theodose, Pierre clement Thiebaud, Caroline Thomas, Kelly Tiercelet, Julie Tisserand, Carole Tomczak, Krystel Torelino, Fatima Touam-Ext, Lilia Toumi, Gustave Toury, Mireille Toy-Miou, Olivia Tran Dinh Thanh Lien, Alexy Trandinh, Jean-Marc Treluyer, Baptiste Trinque, Jennifer Truchot, Sarah Tubiana, Simone Tunesi, Matthieu Turpin, Agathe Turpin, Tomas Urbina, Rafael Usubillaga Narvaez, Yurdagul Uzunhan, Prabakar Vaittinadaayar, Arnaud Valent, Maelle Valentian, Nadia Valin, Hélène Vallet, Marina Vaz, Miguel-Alejandro Vazquezibarra, Benoit Vedie, Laetitia Velly, Celine Verstuyft, Cedric Viallette, Eric Vicaut, Dorothee Vignes, Damien Vimpere, Myriam Virlouvet, Guillaume Voiriot, Lena Voisot, Emmanuel Weiss, Nicolas Weiss, Anaïs Winchenne, Youri Yordanov, Lara Zafrani, Mohamad Zaidan, Wissem Zaidi, Cathia Zak, Aida Zarhrate-Ghoul, Ouassila Zatout, Suzanne Zeino, Michel Zeitouni, Naïma Zemirli, Lorene Zerah, Ounsa Zia, Marianne Ziol, Oceane Zolario, Julien Zuber, Claire Andrejak, François Angoulvant, Delphine Bachelet, Marie Bartoli, Romain Basmaci, Sylvie Behillil, Marine Beluze, Dehbia Benkerrou, Krishna Bhavsar, Lila Bouadma, Sabelline Bouchez, Maude Bouscambert, Minerva Cervantes-Gonzalez, Anissa Chair, Catherine Chirouze, Alexandra Coelho, Sandrine Couffin-Cadiergues, Eric d’Ortenzio, Marie-Pierre Debray, Laurene Deconinck, Dominique Deplanque, Diane Descamps, Mathilde Desvallée, Alpha Diallo, Alphonsine Diouf, Céline Dorival, François Dubos, Brigitte Elharrar, Vincent Enouf, Hélène Esperou, Marina Esposito-Farese, Manuel Etienne, Eglantine Ferrand Devouge, Nathalie Gault, Alexandre Gaymard, Tristan Gigante, Morgane Gilg, Jérémie Guedj, Alexandre Hoctin, Isabelle Hoffmann, Ikram Houas, Jean-Sébastien Hulot, Salma Jaafoura, Florentia Kaguelidou, Sabrina Kali, Antoine Khalil, Coralie Khan, Cédric Laouénan, Samira Laribi, Minh Le, Quentin Le Hingrat, Soizic Le Mestre, Hervé Le Nagard, François-Xavier Lescure, Sophie Letrou, Yves Levy, Bruno Lina, Guillaume Lingas, Jean-Christophe Lucet, Denis Malvy, Marina Mambert, Amina Meziane, Hugo Mouquet, Jimmy Mullaert, Nadège Neant, Duc Nguyen, Marion Noret, Saad Nseir, Aurélie Papadopoulos, Christelle Paul, Nathan Peiffer-Smadja, Thomas Perpoint, Ventzislava Petrov-Sanchez, Gilles Peytavin, Huong Pham, Olivier Picone, Oriane Puéchal, Christian Rabaud, Manuel Rosa-Calatrava, Bénédicte Rossignol, Patrick Rossignol, Carine Roy, Marion Schneider, Richa Su, Coralie Tardivon, Marie-Capucine Tellier, François Téoulé, Olivier Terrier, Jean-François Timsit, Christelle Tual, Sylvie Van Der Werf, Noémie Vanel, Aurélie Veislinger, Benoit Visseaux, Aurélie Wiedemann, Yazdan Yazdanpanah, Loubna Alavoine, Charlotte Charpentier, Aline Dechanet, Jean-Luc Ecobichon, Wahiba Frezouls, Nadhira Houhou, Jonathan Lehacaut, Pauline Manchon, Mariama Nouroudine, Caroline Quintin, Michael Thy, Sylvie van der Werf, Valérie Vignali, Abir Chahine, Nawal Waucquier, Maria-Claire Migaud, Félix Djossou, Mayka Mergeay-Fabre, Aude Lucarelli, Magalie Demar, Léa Bruneau, Patrick Gérardin, Adrien Maillot, Christine Payet, Bruno Laviolle, Fabrice Laine, Christophe Paris, Mireille Desille-Dugast, Julie Fouchard, Thierry Pistone, Pauline Perreau, Valérie Gissot, Carole L.E. Goas, Samatha Montagne, Lucie Richard, Kévin Bouiller, Maxime Desmarets, Alexandre Meunier, Marilou Bourgeon, Benjamin Lefévre, Hélène Jeulin, Karine Legrand, Sandra Lomazzi, Bernard Tardy, Amandine Gagneux-Brunon, Frédérique Bertholon, Elisabeth Botelho-Nevers, Christelle Kouakam, Leturque Nicolas, Layidé Roufai, Karine Amat, Hélène Espérou, Samia Hendou, Giuseppe Foti, Giuseppe Citerio, Ernesto Contro, Alberto Pesci, Maria Grazia Valsecchi, Marina Cazzaniga, Giacomo Bellani, Jorge Abad, Giulia Accordino, Micol Angelini, Sergio Aguilera-Albesa, Aina Aguiló-Cucurull, Esra Akyüz Özkan, Ilad Alavi Darazam, Jonathan Antonio Roblero Albisures, Juan C. Aldave, Miquel Alfonso Ramos, Taj Ali Khan, Anna Aliberti, Seyed Alireza Nadji, Gulsum Alkan, Suzan A. AlKhater, Jerome Allardet-Servent, Luis M. Allende, Rebeca Alonso-Arias, Mohammed S. Alshahrani, Laia Alsina, Zahir Amoura, Arnau Antolí, Romain Arrestier, Mélodie Aubart, Teresa Auguet, Iryna Avramenko, Gökhan Aytekin, Axelle Azot, Seiamak Bahram, Fanny Bajolle, Fausto Baldanti, Aurélie Baldolli, Maite Ballester, Benoit Barrou, Federica Barzaghi, Sabrina Basso, Gulsum Iclal Bayhan, Liliana Bezrodnik, Agurtzane Bilbao, Geraldine Blanchard-Rohner, Ignacio Blanco, Adeline Blandinières, Daniel Blázquez-Gamero, Marketa Bloomfield, Mireia Bolivar-Prados, Raphael Borie, Elisabeth Botdhlo-Nevers, Aurore Bousquet, David Boutolleau, Claire Bouvattier, Oksana Boyarchuk, Juliette Bravais, M. Luisa Briones, Marie-Eve Brunner, Raffaele Bruno, Maria Rita P. Bueno, Huda Bukhari, Jacinta Bustamante, Juan José Cáceres Agra, Ruggero Capra, Raphael Carapito, Maria Carrabba, Carlos Casasnovas, Marion Caseris, Irene Cassaniti, Martin Castelle, Francesco Castelli, Martín Castillo de Vera, Mateus V. Castro, Emilie Catherinot, Jale Bengi Celik, Alessandro Ceschi, Martin Chalumeau, Bruno Charbit, Cécile Boulanger, Père Clavé, Bonaventura Clotet, Anna Codina, Cloé Comarmond, Patrizia Comoli, Angelo G. Corsico, Taner Coşkuner, Aleksandar Cvetkovski, Cyril Cyrus, David Dalmau, François Danion, David Ross Darley, Vincent Das, Nicolas Dauby, Stéphane Dauger, Paul De Munte, Loic de Pontual, Amin Dehban, Geoffroy Delplancq, Isabelle Desguerre, Antonio Di Sabatino, Jean-Luc Diehl, Stephanie Dobbelaere, Elena Domínguez-Garrido, Clément Dubost, Olov Ekwall, Şefika Elmas Bozdemir, Marwa H. Elnagdy, Melike Emiroglu, Akifumi Endo, Emine Hafize Erdeniz, Selma Erol Aytekin, Maria Pilar Etxart Lasa, Romain Euvrard, Giovanna Fabio, Laurence Faivre, Antonin Falck, Muriel Fartoukh, Morgane Faure, Miguel Fernandez Arquero, Ricard Ferrer, Jose Ferreres, Bruno Francois, Victoria Fumadó, Kitty S.C. Fung, Francesca Fusco, Alenka Gagro, Blanca Garcia Solis, Pierre Garçon, Pascale Gaussem, Zeynep Gayretli, Juana Gil-Herrera, Laurent Gilardin, Audrey Giraud Gatineau, Mònica Girona-Alarcón, Karen Alejandra Cifuentes Godínez, Jean-Christophe Goffard, Nacho Gonzales, Luis I. Gonzalez-Granado, Rafaela González-Montelongo, Antoine Guerder, Belgin Gülhan, Victor Daniel Gumucio, Leif Gunnar Hanitsch, Jan Gunst, Marta Gut, Jérôme Hadjadj, Selda Hancerli, Tetyana Hariyan, Nevin Hatipoglu, Deniz Heppekcan, Elisa Hernandez-Brito, Po-ki Ho, María Soledad Holanda-Peña, Juan P. Horcajada, Sami Hraiech, Linda Humbert, Ivan F.N. Hung, Alejandro D. Iglesias, Antonio Íñigo-Campos, Matthieu Jamme, María Jesús Arranz, Marie-Thérèse Jimeno, Iolanda Jordan, Saliha Kanık-Yüksek, Yalcin Kara, Aydın Karahan, Adem Karbuz, Kadriye Kart Yasar, Ozgur Kasapcopur, Kenichi Kashimada, Sevgi Keles, Yasemin Kendir Demirkol, Yasutoshi Kido, Can Kizil, Ahmet Osman Kılıç, Adam Klocperk, Antonia Koutsoukou, Zbigniew J. Król, Hatem Ksouri, Paul Kuentz, Arthur M.C. Kwan, Yat Wah M. Kwan, Janette S.Y. Kwok, Jean-Christophe Lagier, David S.Y. Lam, Vicky Lampropoulou, Fleur Le Bourgeois, Yee-Sin Leo, Rafael Leon Lopez, Daniel Leung, Michael Levin, Michael Levy, Romain Lévy, Zhi Li, Daniele Lilleri, Edson Jose Adrian Bolanos Lima, Agnes Linglart, Eduardo López-Collazo, José M. Lorenzo-Salazar, Céline Louapre, Catherine Lubetzki, Kwok-Cheung Lung, Charles-Edouard Luyt, David C. Lye, Cinthia Magnone, Enrico Marchioni, Carola Marioli, Majid Marjani, Laura Marques, Jesus Marquez Pereira, Andrea Martín-Nalda, David Martínez Pueyo, Javier Martinez-Picado, Iciar Marzana, Carmen Mata-Martínez, Alexis Mathian, Larissa R.B. Matos, Gail V. Matthews, Julien Mayaux, Raquel McLaughlin-Garcia, Philippe Meersseman, Jean-Louis Mège, Armand Mekontso-Dessap, Isabelle Melki, Federica Meloni, Jean-François Meritet, Paolo Merlani, Özge Metin Akcan, Mehdi Mezidi, Isabelle Migeotte, Maude Millereux, Matthieu Million, Tristan Mirault, Clotilde Mircher, Mehdi Mirsaeidi, Yoko Mizoguchi, Bhavi P. Modi, Francesco Mojoli, Elsa Moncomble, Abián Montesdeoca Melián, Antonio Morales Martinez, Francisco Morandeira, Pierre-Emmanuel Morange, Clémence Mordacq, Guillaume Morelle, Stéphane J. Mouly, Adrián Muñoz-Barrera, Cyril Nafati, Shintaro Nagashima, Yu Nakagama, Bénédicte Neven, João Farela Neves, Yuk-Yung Ng, Hubert Nielly, Yeray Novoa Medina, Esmeralda Nuñez Cuadros, Semsi Nur Karabela, J. Gonzalo Ocejo-Vinyals, Mehdi Oualha, Amani Ouedrani, Tayfun Özçelik, Aslinur Ozkaya-Parlakay, Michele Pagani, Maria Papadaki, Philippe Parola, Tiffany Pascreau, Stéphane Paul, Estela Paz-Artal, Sigifredo Pedraza, Nancy Carolina González Pellecer, Silvia Pellegrini, Rebeca Pérez de Diego, Xosé Luis Pérez-Fernández, Aurélien Philippe, Quentin Philippot, Adrien Picod, Marc Pineton de Chambrun, Antonio Piralla, Laura Planas-Serra, Dominique Ploin, Julien Poissy, Géraldine Poncelet, Garyphallia Poulakou, Marie S. Pouletty, Persia Pourshahnazari, Jia Li Qiu-Chen, Paul Quentric, Thomas Rambaud, Didier Raoult, Violette Raoult, Anne-Sophie Rebillat, Claire Redin, Léa Resmini, Pilar Ricart, Jean-Christophe Richard, Raúl Rigo-Bonnin, Nadia Rivet, Jacques G. Rivière, Gemma Rocamora-Blanch, Mathieu P. Rodero, Carlos Rodrigo, Luis Antonio Rodriguez, Carlos Rodriguez-Gallego, Agustí Rodriguez-Palmero, Carolina Soledad Romero, Anya Rothenbuhler, Damien Roux, Nikoletta Rovina, Flore Rozenberg, Yvon Ruch, Montse Ruiz, Maria Yolanda Ruiz del Prado, Juan Carlos Ruiz-Rodriguez, Joan Sabater-Riera, Kai Saks, Maria Salagianni, Oliver Sanchez, Adrián Sánchez-Montalvá, Silvia Sánchez-Ramón, Laire Schidlowski, Agatha Schluter, Julien Schmidt, Matthieu Schmidt, Catharina Schuetz, Cyril E. Schweitzer, Francesco Scolari, Luis Seijo, Analia Gisela Seminario, Piseth Seng, Sevtap Senoglu, Mikko Seppänen, Alex Serra Llovich, Virginie Siguret, Eleni Siouti, David M. Smadja, Nikaia Smith, Ali Sobh, Xavier Solanich, Jordi Solé-Violán, Catherine Soler, Betül Sözeri, Giulia Maria Stella, Yuriy Stepanovskiy, Annabelle Stoclin, Fabio Taccone, Jean-Luc Taupin, Simon J. Tavernier, Loreto Vidaur Tello, Benjamin Terrier, Guillaume Thiery, Karolina Thorn, Caroline Thumerelle, Imran Tipu, Martin Tolstrup, Gabriele Tomasoni, Julie Toubiana, Josep Trenado Alvarez, Vasiliki Triantafyllia, Jesús Troya, Owen T.Y. Tsang, Liina Tserel, Eugene Y.K. Tso, Alessandra Tucci, Şadiye Kübra Tüter Öz, Matilde Valeria Ursini, Takanori Utsumi, Pierre Vabres, Juan Valencia-Ramos, Ana Maria Van Den Rym, Isabelle Vandernoot, Valentina Velez-Santamaria, Silvia Patricia Zuniga Veliz, Mateus C. Vidigal, Sébastien Viel, Cédric Villain, Marie E. Vilaire-Meunier, Judit Villar-García, Audrey Vincent, Dimitri Van der Linden, Alla Volokha, Fanny Vuotto, Els Wauters, Alan K.L. Wu, Tak-Chiu Wu, Aysun Yahşi, Osman Yesilbas, Mehmet Yildiz, Barnaby E. Young, Ufuk Yükselmiş, Marco Zecca, Valentina Zuccaro, Jens Van Praet, Bart N. Lambrecht, Eva Van Braeckel, Cédric Bosteels, Levi Hoste, Eric Hoste, Fré Bauters, Jozefien De Clercq, Catherine Heijmans, Hans Slabbynck, Leslie Naesens, Benoit Florkin, Mary-Anne Young, Amanda Willis, Paloma Lapuente-Suanzes, Ana de Andrés-Martín, Matilda Berkell, Valerio Carelli, Alessia Fiorentino, Surbhi Malhotra, Alessandro Mattiaccio, Tommaso Pippucci, Marco Seri, Evelina Tacconelli, Michiel van Agtmael, Anne Geke Algera, Brent Appelman, Frank van Baarle, Diane Bax, Martijn Beudel, Harm Jan Bogaard, Marije Bomers, Peter Bonta, Lieuwe Bos, Michela Botta, Justin de Brabander, Godelieve de Bree, Sanne de Bruin, David T.P. Buis, Marianna Bugiani, Esther Bulle, Osoul Chouchane, Alex Cloherty, Mirjam Dijkstra, Dave A. Dongelmans, Romein W.G. Dujardin, Paul Elbers, Lucas Fleuren, Suzanne Geerlings, Theo Geijtenbeek, Armand Girbes, Bram Goorhuis, Martin P. Grobusch, Florianne Hafkamp, Laura Hagens, Jorg Hamann, Vanessa Harris, Robert Hemke, Sabine M. Hermans, Leo Heunks, Markus Hollmann, Janneke Horn, Joppe W. Hovius, Menno D. de Jong, Rutger Koning, Endry H.T. Lim, Niels van Mourik, Jeaninne Nellen, Esther J. Nossent, Frederique Paulus, Edgar Peters, Dan A.I. Pina-Fuentes, Tom van der Poll, Bennedikt Preckel, Jan M. Prins, Jorinde Raasveld, Tom Reijnders, Maurits C.F. J. de Rotte, Michiel Schinkel, Marcus J. Schultz, Femke A.P. Schrauwen, Alex Schuurmans, Jaap Schuurmans, Kim Sigaloff, Marleen A. Slim, Patrick Smeele, Marry Smit, Cornelis S. Stijnis, Willemke Stilma, Charlotte Teunissen, Patrick Thoral, Anissa M. Tsonas, Pieter R. Tuinman, Marc van der Valk, Denise P. Veelo, Carolien Volleman, Heder de Vries, Lonneke A. Vught, Michèle van Vugt, Dorien Wouters, A.H. Zwinderman, Matthijs C. Brouwer, W. Joost Wiersinga, Alexander P.J. Vlaar, Miranda F. Tompkins, Camille Alba, Daniel N. Hupalo, John Rosenberger, Gauthaman Sukumar, Matthew D. Wilkerson, Xijun Zhang, Justin Lack, Andrew J. Oler, Kerry Dobbs, Ottavia M. Delmonte, Jeffrey J. Danielson, Andrea Biondi, Laura Rachele Bettini, Mariella D’Angiò, Ilaria Beretta, Luisa Imberti, Alessandra Sottini, Virginia Quaresima, Eugenia Quiros-Roldan, Camillo Rossi, Riccardo Castagnoli, Daniela Montagna, Amelia Licari, and Gian Luigi Marseglia
Subjects: HLA, association, asymptomatic infection, COVID-19, population stratification, Genetics, QH426-470
Abstract: Summary: Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified.
Published: 2024
Full Text: View/download PDF

3. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

Author: Sargsyants, N., Suleymanova, L., Salkic, N., Simonova, M., Nemeth-Blazic, T., Mravcik, V., Kivimets, K., Salupere, R., Butsashvili, M., Soselia, G., Makara, M., Tolmane, I., Jancorienė, L., Stratulat, S., Flisiak, R., Gheorghe, L., Cernat, R., Lakhov, A., Stanevich, O., Jarcuska, P., Peck-Radosavljevic, M., Robaeys, G., Øvrehus, A., Foster, G., Sutinen, J., Farkkila, M., Rautiainen, H., Vuoti, S., Nikolova, D., Pawlotsky, J.M., Rockstroh, J., Sypsa, V., Papatheodoridis, G., Olafsson, S., Feeney, E., Teti, E., Seguin-Devaux, C., Pocock, J., Reiff, S., McDougall, N., Van der Valk, M., Dalgard, O., Tato Marinho, R., Dillon, J., Peters, E., Bojovic, K., Matičič, M., Kåberg, M., Bruggmann, P., Healy, B., Chong, V.H., Yi, S., Tucker, J., Pasaribu, L.R., Tanaka, J., Ashley, E.A., Abu Hassan, M.R., Mohammed, N.S., Chan, H.K., Gidaagaya, S., Kyi, K.P., Hyung Joon, K., Chin, B., Baladjay, P.C., Kao, J.H., Wansom, T., da Cruz, B., Flower, B., Ehsan, E., Al Mahtab, M., Khandu, L., Bhadoria, A.S., Alavi, M., KC, P., Hamid, S., Biryukov, S., Alymbaeva, D., Alaei, A., Bakieva, S., Flichman, D., Carmo, R.F., Valdez, E., Cortes, C.P., Contreras, F., Teran, E., Velez-Moller, P., Jagnarine, T., Mills, M., Goodman-Meza, D., Sánchez, J., Montenegro-Idrogo, J.J., Lugo Canales, A.M., Davy, J., Alexander, A., Gerona, S., Perazzo, R., Balak, D., Kelly-Hanku, A., Fineanganofo, A., Gane, E., Raymond, N., Debzi, N., Sridharan, K., Waked, I., Turner, D., Shibolet, O., Al Muzaini, A., El Nakib, M., Sheriff, D.S., Brahni, T., Essayagh, T., Essayagh, S., Hjaija, D., Al-Naamani, K., Sanai, F.M., Pasquale, H., Bedri, S., Chakroun, M., Ghrabi, A., Akarca, U.S., Falcao, V., Edmond Gbedo, S., Ouoba, S., Nyabenda, F., Rocher Mbella, M., Mahamat Moussa, A., Youssouf, T., Boniface, Y., Akilimali Shindano, T., Hamida, M.E., Mongo, A., Mapapa, C., Desalegn, H., Embinga, E.L.A., Ndow, G., Nartey, Y., Cisse, M., Djalo, M.A., Mugambi, M., Nyakowa, M., Jeuronlon, M.K., Ngoma, J., Manitrala Ramanampamonjy, R., Naik, K., Soyjaudah, M.D., Filipe, E., Nnakelu, E., Serumondo, J., Mbodj, M., Patino, M., Aalto, M.K., Waweru, P., Dagnra, A., Ocama, P., Maghimbi, A., Hamooya, B.M., Katsidzira, L., Rios, C., Thormann, M., Al Marzooqi, N., Al Rand, H.M., Francois, K., Hamoudi, W., Alkharty, M., Skripo, O., Uka, T., Marshall, Alison D, Willing, Alex R, Kairouz, Abe, Cunningham, Evan B, Wheeler, Alice, O’Brien, Nicholas, Perera, Vidura, Ward, John W, Hiebert, Lindsey, Degenhardt, Louisa, Hajarizadeh, Behzad, Colledge, Samantha, Hickman, Matthew, Jawad, Danielle, Lazarus, Jeffrey V, Matthews, Gail V, Scheibe, Andrew, Vickerman, Peter, Dore, Gregory J, and Grebely, Jason
Published: 2024
Full Text: View/download PDF

4. Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy

Author: Singh, Kasha P., Avihingsanon, Anchalee, Zerbato, Jennifer M., Zhao, Wei, Braat, Sabine, Tennakoon, Surekha, Rhodes, Ajantha, Matthews, Gail V., Fairley, Christopher K., Sasadeusz, Joe, Crane, Megan, Audsley, Jennifer, and Lewin, Sharon R.
Published: 2024
Full Text: View/download PDF

5. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies

Author: Hellard, Margaret E, Sacks-Davis, Rachel, van Santen, Daniela K, Stewart, Ashleigh, Ke, Tianhui, Zhang, Yanqin, Stoove, Mark, Guy, Rebecca, Pedrana, Alisa, Asselin, Jason, Dawe, Joshua, Wilkinson, Anna, Boyd, Anders, Smit, Colette, van der Valk, Marc, Schinkel, Janke, Wittkop, Linda, Salmon, Dominique, Sogni, Philippe, Esterle, Laure, Gilbert, Camille, Merchadou, Laurence, Gillet, Stephanie, Khan, Coralie, Bonnet, Fabrice, Leleux, Olivier, Le Marec, Fabien, Perrier, Adelaide, Matthews, Gail, Shaw, Ineke, Martinello, Marianne, Applegate, Tanya, Carson, Joanne, Doyle, Joseph S, Harney, Brendan, Bryant, Melissa, Jarrin Vera, Inmaculada, Berenguer, Juan, Alejos, Belen, Lazarus, Jeffrey V, Moreno, Cristina, Izquierdo, Rebecca, Rava, Marta, Klein, Marina, Wang, Shouao, Lumia, Jessica, Pexos, Costa, Peiris, Hansi, Saeed, Sahar, Moodie, Erica, Young, Jim, Pick, Neora, Conway, Brian, Hull, Mark, Wong, Alex, Gill, John, Barrett, Lisa, Cohen, Jeff, Cox, Joseph, Cote, Pierre, Haider, Shariq, Rouleau, Danielle, Vachon, Marie-Louise, Rachlis, Anita, Sandre, Roger, Walmsley, Sharon, Sadr, Aida, Cooper, Curtis, Sanche, Steve, Rauch, Andri, Mugglin, Catrina, Salazar-Viscaya, Luisa, Kusejko, Katharina, Prins, Maria, Hage, Kris, Lacombe, Karine, Requena, Maria-Bernada, Girard, Pierre-Marie, Brucker, Matthieu, Vincensini, Jean-Paul, Jarrin, Inmaculada, Requena, Maria-Bernarda, Matthews, Gail V, Martin, Natasha K, Spelman, Tim, and Hellard, Margaret
Published: 2024
Full Text: View/download PDF

6. The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC

Author: Lucette A. Cysique, David Jakabek, Sophia G. Bracken, Yasmin Allen‐Davidian, Benjamin Heng, Sharron Chow, Mona Dehhaghi, Ananda Staats Pires, David R. Darley, Anthony Byrne, Chansavath Phetsouphanh, Anthony Kelleher, Gregory J. Dore, Gail V. Matthews, Gilles J. Guillemin, and Bruce J. Brew
Subjects: Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract: Abstract Objective To determine the prevalence and natural history of post‐acute COVID‐19 objective cognitive impairment and function, and their relationship to demographic, clinical factors, post‐acute sequelae of COVID‐19 (PASC), and biomarkers. Methods A total of 128 post‐acute COVID‐19 patients (age = 46 ± 15; 42% women, acute disease severity: not hospitalized: 38.6% mild: 0–1 symptoms, 52% 2+ symptoms; 9.4% hospitalized) completed standard cognition, olfaction, and mental health examinations 2‐, 4‐, and 12‐month post diagnosis. Over the same time frame, WHO‐defined PASC was determined. Blood cytokines, peripheral neurobiomarkers, and kynurenine pathway (KP) metabolites were measured. Objective cognitive function was demographically/practice corrected, and impairment prevalence was determined using the evidence‐based Global Deficit Score method to detect at least mild cognitive impairment (GDS > 0.5). Linear mixed effect regression models with time effect (month post diagnosis) evaluated the relationships to cognition. Results Across the 12‐month study period, mild to moderate cognitive impairment ranged from 16% to 26%, and 46.5% were impaired at least once. Impairment associated with poorer work capacity (p
Published: 2023
Full Text: View/download PDF

7. Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study

Author: Martinello, Marianne, Bhagani, Sanjay, Shaw, David, Orkin, Chloe, Cooke, Graham, Gane, Edward, Iser, David, Ustianowski, Andrew, Kulasegaram, Ranjababu, Stedman, Catherine, Tu, Elise, Grebely, Jason, Dore, Gregory J., Nelson, Mark, and Matthews, Gail V.
Published: 2023
Full Text: View/download PDF

8. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT

Author: Emmanuelle Papot, Simone Jacoby, Dona Arlinda, Anchalee Avihingsanon, Iskandar Azwa, Margaret Borok, Dannae Brown, Mohamed Cissé, Sounkalo Dao, Nnakelu Eriobu, Richard Kaplan, Muhammad Karyana, Nagalingeswaran Kumarasamy, Johnnie Lee, Marcelo H. Losso, Gail V. Matthews, Leonardo Perelis, Carmen Perez-Casas, Kiat Ruxrungtham, Melynda Watkins, H. Clifford Lane, Anthony Kelleher, Matthew Law, and Mark N. Polizzotto
Subjects: mams, randomised-clinical trial, fixed-dose combinations, drug-sparing regimens, tld, hiv, Infectious and parasitic diseases, RC109-216
Abstract: A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART is failing. At inception, it compared a standard of care of boosted darunavir with two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to the novel NRTI-sparing regimen of boosted darunavir with dolutegravir. Implemented in 2017, participating sites were across Africa, Asia and Latin America. Around the time of implementation, the World Health Organization updated its treatment guidelines and recommended scaling up tenofovir disoproxil fumarate-lamivudine-dolutegravir (TLD). This situation pushed D2EFT investigators to consider the impact of the roll-out of TLD on the D2EFT research question. The protocol team agreed it was important to study TLD in second-line when an NNRTI regimen was failing, and focused on options to expedite the work by studying the question within the existing trial and network. All key issues (statistical, programmatic and financial) were reviewed to assess the benefits and risks of adding a third arm to the ongoing study, as opposed to developing a new randomised clinical trial with the same control arm and within the same network. The development of a new trial was deemed to be longer than adding a third arm, and to create a challenging situation with two competing clinical trials at the same sites which would slow down recruitment and impair both trials. On the other hand, adding a third arm would be demanding in terms of operationalisation, increased sample size and statistical biases to control. The optimal strategy was deemed to be the addition of a third arm, arriving retrospectively at a simplified multi-arm multi-stage clinical trial design to achieve statistical validity. The D2EFT study maintains additional value in a quickly evolving second-line ART strategy allowed by the progress in global access to ART.
Published: 2022
Full Text: View/download PDF

9. Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT study

Author: Joanne M. Carson, Sebastiano Barbieri, Evan Cunningham, Eric Mao, Marc van derValk, Jürgen K. Rockstroh, Margaret Hellard, Arthur Kim, Sanjay Bhagani, Jordan J. Feld, Ed Gane, Maria C. Thurnheer, Julie Bruneau, Elise Tu, Gregory J. Dore, Gail V. Matthews, Marianne Martinello, and the REACT study group
Subjects: HCV, HIV, STI, GBM, PWID, reinfection, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Introduction Exploration of sexual and drug use behaviours following treatment for recent hepatitis C virus (HCV) is limited. This analysis modelled behavioural trajectories following treatment for recent HCV and assessed reinfection. Methods Participants treated for recent HCV in an international trial (enrolled 2017–2019) were followed at 3‐monthly intervals for up to 2 years to assess longitudinal behaviours. Population‐averaged changes were assessed using generalized estimating equations. Distinct behavioural trajectories were identified using group‐based trajectory modelling. HCV reinfection incidence was calculated using person‐years (PY) of observation. Results During the follow‐up of 212 participants (84% gay and bisexual men [GBM]; 69% HIV; 26% current injecting drug use [IDU]), behavioural trajectories for IDU and stimulant use (past month) did not change. However, population‐averaged decreases in the likelihood of daily IDU (adjusted odds ratio [AOR] 0.83; 95% CI 0.72, 0.95) and opioid use (AOR 0.84; 95% CI 0.75, 0.93) were observed. Among GBM, behavioural trajectories for chemsex did not change. Population‐averaged decreases in condomless anal intercourse with casual male partners (CAI‐CMP) (AOR 0.95; 95% CI 0.90, 0.99) and group‐sex (AOR 0.86; 95% CI 0.80, 0.93) were observed, but masked distinct trajectories. While a proportion had a decreased probability of CAI‐CMP (23%) and group‐sex (59%) post‐treatment, a substantial proportion retained a high probability of these behaviours. High HCV reinfection incidence was observed for the sustained high probability IDU (33.0/100 PY; 95% CI 17.7, 61.3) and chemsex (23.3/100 PY; 95% CI 14.5, 37.5) trajectories. Conclusions Limited sexual and drug use behavioural change was observed following treatment for recent HCV, supporting access to surveillance and (re)treatment.
Published: 2023
Full Text: View/download PDF

10. National trends in retreatment of HCV due to reinfection or treatment failure in Australia

Author: Carson, Joanne M., Barbieri, Sebastiano, Matthews, Gail V., Dore, Gregory J., and Hajarizadeh, Behzad
Published: 2023
Full Text: View/download PDF

11. Reinfection incidence and risk among people treated for recent hepatitis C virus infection

Author: Martinello, Marianne, Carson, Joanne M., Van Der Valk, Marc, Rockstroh, Jürgen K., Ingiliz, Patrick, Hellard, Margaret, Nelson, Mark, Lutz, Thomas, Bhagani, Sanjay, Kim, Arthur Y., Hull, Mark, Cordes, Christiane, Moon, Juhi, Feld, Jordan J., Gane, Ed, Rauch, Andri, Bruneau, Julie, Tu, Elise, Applegate, Tanya, Grebely, Jason, Dore, Gregory J., and Matthews, Gail V.
Published: 2023
Full Text: View/download PDF

12. Perceptions of hepatitis C treatment and reinfection risk among HIV-positive men who have sex with men and engage in high risk behaviours for hepatitis C transmission: The CEASE qualitative study

Author: Marshall, Alison D., Martinello, Marianne, Treloar, Carla, and Matthews, Gail V.
Published: 2022
Full Text: View/download PDF

13. Platform for isolation and characterization of SARS-CoV-2 variants enables rapid characterization of Omicron in Australia

Author: Aggarwal, Anupriya, Stella, Alberto Ospina, Walker, Gregory, Akerman, Anouschka, Esneau, Camille, Milogiannakis, Vanessa, Burnett, Deborah L., McAllery, Samantha, Silva, Mariana Ruiz, Lu, Yonghui, Foster, Charles S. P., Brilot, Fabienne, Pillay, Aleha, Van Hal, Sabastiaan, Mathivanan, Vennila, Fichter, Christina, Kindinger, Andrea, Hoppe, Alexandra Carey, Munier, Mee Ling, Amatayakul-Chantler, Supavadee, Roth, Nathan, Coppola, Germano, Symonds, Geoff P., Schofield, Peter, Jackson, Jennifer, Lenthall, Helen, Henry, Jake Y., Mazigi, Ohan, Jäck, Hans-Martin, Davenport, Miles P., Darley, David R., Matthews, Gail V., Khoury, David S., Cromer, Deborah, Goodnow, Christopher C., Christ, Daniel, Robosa, Roselle, Starck, Damien J., Bartlett, Nathan W., Rawlinson, William D., Kelleher, Anthony D., and Turville, Stuart G.
Published: 2022
Full Text: View/download PDF

14. Characteristics Associated with Monitoring and Treatment of Chronic Hepatitis B in a Large Cohort of Australian Adults

Author: He, Wen-Qiang, Matthews, Gail V., and Liu, Bette
Published: 2022
Full Text: View/download PDF

15. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

Author: Hosseini-Hooshyar, Samira, Hajarizadeh, Behzad, Bajis, Sahar, Law, Matthew, Janjua, Naveed Z, Fierer, Daniel S, Chromy, David, Rockstroh, Jürgen K, Martin, Thomas C S, Ingiliz, Patrick, Hung, Chien-Ching, Dore, Gregory J, Martinello, Marianne, and Matthews, Gail V
Published: 2022
Full Text: View/download PDF

16. Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study.

Author: Nyein, Phyo Pyae, Petoumenos, Kathy, Borok, Margaret, Eriobu, Nnakelu, Kumarasamy, Nagalingeswaran, Avihingsanon, Anchalee, Azwa, Iskandar, Dao, Sounkalo, Cisse, Mohamed, Dharan, Nila J, Hanson, Josh, and Matthews, Gail V
Abstract: In this randomized controlled study, individuals taking dolutegravir+darunavir/ritonavir had greater increases in systolic and diastolic blood pressure than those taking 2 nucleoside reverse-transcriptase inhibitors+darunavir/ritonavir at week-48. The difference remained significant after controlling for confounding factors, including weight gain. [ABSTRACT FROM AUTHOR]
Published: 2025
Full Text: View/download PDF

17. Unsuccessful Direct Acting Antiviral Hepatitis C Treatment Among People With HIV: Findings From an International Cohort.

Author: Harney, Brendan L., Sacks‐Davis, Rachel, van Santen, Daniela K., Stewart, Ashleigh C., Matthews, Gail V., Carson, Joanne M., Klein, Marina B., Lacombe, Karine, Wittkop, Linda, Salmon, Dominque, Leleux, Olivier, Merchadou, Laurence, van der Valk, Marc, Smit, Colette, Prins, Maria, Boyd, Anders, Berenguer, Juan, Jarrin, Inmaculada, Rauch, Andri, and Hellard, Margaret E.
Subjects: DRUG abuse, END of treatment, HEPATITIS C virus, HEPATITIS C, TREATMENT effectiveness
Abstract: Background: Historically, hepatitis C virus (HCV) was difficult to treat among people with HIV. However, treatment with direct‐acting antivirals (DAAs) results in 90%–95% of people being cured. There is a need to understand why a proportion of people are not cured. We aimed to examine characteristics that may indicate an increased probability of unsuccessful DAA HCV treatment. Methods: Data were from the International Collaboration on Hepatitis C Elimination in HIV Cohorts. People who commenced DAA HCV treatment between 2014 and 2019 were included. Unsuccessful treatment was defined as a positive HCV RNA test at a person's first RNA test at least 4 weeks (SVR4+) following the end of treatment. Multivariable mixed‐effects logistic regression was used to examine characteristics associated with unsuccessful treatment. Results: Of 4468 people who commenced DAA treatment, 4098 (91.7%) had an SVR test 4+ weeks following the end of treatment, 207 (5%) of whom were unsuccessfully treated. Compared to a CD4+ cell count > 500 cells/mm3, cell counts < 200 (aOR 1.81, 95%CI 1.00–3.29) and between 200 and 349 (aOR 1.95, 95%CI 1.30–2.93) were associated with increased odds of unsuccessful treatment. Among 1921 people with data on injection drug use in the 12 months prior to treatment, there was some evidence that recent injection drug use was associated with increased odds of unsuccessful treatment; however, this was not statistically significant (aOR 1.67, 95%CI 0.99–2.82). Conclusions: The overwhelming majority of people were successfully treated for HCV. Overall, 5% of those with an SVR4+ test were unsuccessfully treated; this was more likely among people with evidence of immunodeficiency and those who reported recently injecting drugs. [ABSTRACT FROM AUTHOR]
Published: 2025
Full Text: View/download PDF

18. Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014–2023).

Author: Martinello, Marianne, Carson, Joanne M, Post, Jeffrey J, Finlayson, Robert, Baker, David, Read, Phillip, Shaw, David, Bloch, Mark, Doyle, Joseph, Hellard, Margaret, Filep, Ecaterina, Hosseini-Hooshyar, Samira, Dore, Gregory J, and Matthews, Gail V
Subjects: HEPATITIS C virus, BISEXUAL men, HIV-positive persons, HEPATITIS C, GAY men
Abstract: Background Approximately 10% of people with HIV in Australia had active hepatitis C virus (HCV) infection prior to availability of government-subsidized direct-acting antiviral (DAA) therapy in 2016. This analysis evaluated progress toward HCV elimination among people with HIV in Australia between 2014 and 2023. Methods The CEASE cohort study enrolled adults with HIV with past or current HCV infection (anti-HCV antibody positive) from 14 primary and tertiary clinics. Biobehavioral, clinical, and virologic data were collected at enrollment (2014–2016), follow-up 1 (2017–2018), and follow-up 2 (2021–2023). HCV treatment uptake, outcome, and HCV RNA prevalence (current infection) were evaluated. Death and HCV reinfection incidence and risk were assessed. Results Of 402 participants, 341 (85%) had current HCV infection (RNA positive) at enrollment. Among the sample, 83% were gay and bisexual men, 13% had cirrhosis, and 80% had a history of injecting drug use (42%, past 6 months). DAA treatment was scaled up rapidly, with cumulative treatment uptake increasing from 12% in 2014 to 2015 to 92% in 2022 to 2023. HCV RNA prevalence declined from 85% (95% CI, 81%–88%) at enrollment (2014–2016) to 8% (95% CI, 6%–12%) at follow-up 1 (2017–2018) and 0.5% (95% CI, 0%–3%) at follow-up 2 (2020–2023). Sixteen reinfections occurred (incidence, 1.41 per 100 person-years; 95% CI,.81–2.29) as well as 30 deaths (incidence, 1.64 per 100 person-years; 95% CI, 1.11–2.34). HCV reinfection incidence declined over time while mortality remained stable. Conclusions Universal access and rapid DAA uptake were associated with a dramatic reduction in HCV prevalence and reinfection incidence among people with HIV to levels consistent with microelimination. Registration: NCT02102451 (ClinicalTrials.gov). [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

19. High Effectiveness of Broad Access Direct‐Acting Antiviral Therapy for Hepatitis C in an Australian Real‐World Cohort: The REACH‐C Study

Author: Jasmine Yee, Joanne M. Carson, Behzad Hajarizadeh, Joshua Hanson, James O’Beirne, David Iser, Phillip Read, Anne Balcomb, Joseph S. Doyle, Jane Davies, Marianne Martinello, Philiipa Marks, Gregory J. Dore, Gail V. Matthews, and the REACH‐C Study Group
Subjects: Diseases of the digestive system. Gastroenterology, RC799-869
Abstract: Australia was one of the first countries with unrestricted access to government subsidized direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus. This study assessed real‐world DAA treatment outcomes across a diverse range of Australian clinical services and evaluated factors associated with successful treatment and loss to follow‐up. Real‐world Effectiveness of Antiviral therapy in Chronic Hepatitis C (REACH‐C) consisted a national observational cohort of 96 clinical services including specialist clinics and less traditional settings such as general practice. Data were obtained on consecutive individuals who commenced DAAs from March 2016 to June 2019. Effectiveness was assessed by sustained virological response ≥12 weeks following treatment (SVR) using intention‐to‐treat (ITT) and per‐protocol (PP) analyses. Within REACH‐C, 10,843 individuals initiated DAAs (male 69%; ≥50 years 52%; cirrhosis 22%). SVR data were available in 85% (9,174 of 10,843). SVR was 81% (8,750 of 10,843) by ITT and 95% (8,750 of 9,174) by PP. High SVR (≥92%) was observed across all service types and participant characteristics. Male gender (adjusted odds ratio [aOR] 0.56, 95% confidence interval [CI] 0.43‐0.72), cirrhosis (aOR 0.52, 95% CI 0.41‐0.64), recent injecting drug use (IDU; aOR 0.64, 95% CI 0.46‐0.91) and previous DAA treatment (aOR 0.50, 95% CI 0.28‐0.90) decreased the likelihood of achieving SVR. Multiple factors modified the likelihood of loss to follow‐up including IDU ± opioid agonist therapy (OAT; IDU only: aOR 1.75, 95% CI 1.44‐2.11; IDU + OAT: aOR 1.39, 95% CI 1.11‐1.74; OAT only, aOR 1.36; 95% CI 1.13‐1.68) and age (aOR 0.97, 95% CI 0.97‐0.98). Conclusion: Treatment response was high in a diverse population and through a broad range of services following universal access to DAA therapy. Loss to follow‐up presents a real‐world challenge. Younger people who inject drugs were more likely to disengage from care, requiring innovative strategies to retain them in follow‐up.
Published: 2022
Full Text: View/download PDF

20. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection

Author: Phetsouphanh, Chansavath, Darley, David R., Wilson, Daniel B., Howe, Annett, Munier, C. Mee Ling, Patel, Sheila K., Juno, Jennifer A., Burrell, Louise M., Kent, Stephen J., Dore, Gregory J., Kelleher, Anthony D., and Matthews, Gail V.
Published: 2022
Full Text: View/download PDF

21. Clinical and laboratory features of COVID-19 illness and outcomes in immunocompromised individuals during the first pandemic wave in Sydney, Australia

Author: Nila J. Dharan, Sarah C. Sasson, Golo Ahlenstiel, Christopher R. Andersen, Mark Bloch, Griselda Buckland, Nada Hamad, Win Min Han, Anthony D. Kelleher, Georgina V. Long, Gail V. Matthews, Michael M. Mina, Emmanuelle Papot, Kathy Petoumenos, Sanjay Swaminathan, Barbara Withers, James Yun, and Mark N. Polizzotto
Subjects: Medicine, Science
Published: 2023

22. High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells

Author: Chansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, Vera Klemm, Annett Howe, Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, Alberto Ospina Stella, Romain Rouet, Peter Schofield, Megan L. Faulks, Hannah Law, Thidarat Danwilai, Mitchell Starr, C. Mee Ling Munier, Daniel Christ, Mandeep Singh, Peter I. Croucher, Fabienne Brilot-Turville, Stuart Turville, Tri Giang Phan, Gregory J. Dore, David Darley, Philip Cunningham, Gail V. Matthews, Anthony D. Kelleher, and John J. Zaunders
Subjects: SARS-CoV-2, neutralizing antibodies, CD4 T cells, CD4 function, proliferation, Immunologic diseases. Allergy, RC581-607
Abstract: BackgroundLong-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated immunity, is required in a very large majority of the population in order to reduce ongoing disease burden.MethodsWe have investigated the association between memory CD4 and CD8 T cells and levels of neutralizing antibodies in convalescent COVID-19 subjects.FindingsHigher titres of convalescent neutralizing antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously in vitro. Conversely, up to half of convalescent individuals had low neutralizing antibody titres together with a lack of receptor binding domain (RBD)-specific memory CD4 T cells. These low antibody subjects had other, non-RBD, spike-specific CD4 T cells, but with more of an inhibitory Foxp3+ and CTLA-4+ cell phenotype, in contrast to the effector T-bet+, cytotoxic granzymes+ and perforin+ cells seen in RBD-specific memory CD4 T cells from high antibody subjects. Single cell transcriptomics of antigen-specific CD4+ T cells from high antibody subjects similarly revealed heterogenous RBD-specific CD4+ T cells that comprised central memory, transitional memory and Tregs, as well as cytotoxic clusters containing diverse TCR repertoires, in individuals with high antibody levels. However, vaccination of low antibody convalescent individuals led to a slight but significant improvement in RBD-specific memory CD4 T cells and increased neutralizing antibody titres.InterpretationOur results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-region should be prioritized in booster vaccines.
Published: 2022
Full Text: View/download PDF

23. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection

Author: van der Valk, Marc, Hellard, Margaret, Gane, Ed, Rauch, Andri, Bruneau, Julie, Kim, Arthur, Bhagani, Sanjay, Dore, Greg, Marks, Pip, Matthews, Gail, Grebely, Jason, Petoumenos, Kathy, Martinello, Marianne, Applegate, Tanya, Feld, Jordan, Rockstroh, Jürgen, Amjad, Sophia, Tu, Elise, Tamaddoni, Mahshid, Thurnheer, Maria Christine, Gilleece, Yvonne, Nelson, Mark, Fraser, Chris, Moriggia, Alberto, Lutz, Thomas, Moon, Juhi, Read, Phillip, Kim, Arthur Y., Ustianowski, Andrew, Cordes, Christiane, Shaw, David, Sasadeusz, Joe, Hull, Mark, Braun, Dominique, Ingiliz, Patrick, Matthews, Gail V., Van der Valk, Marc, Rockstroh, Juergen, Feld, Jordan J., Thurnheer, Christine, Applegate, Tanya L., Marks, Phillipa, and Dore, Gregory J.
Published: 2021
Full Text: View/download PDF

24. Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case–Control Diagnostic Validation Study

Author: Kris Hage, Marita van de Kerkhof, Anders Boyd, Joanne M. Carson, Astrid M. Newsum, Amy Matser, Marc van der Valk, Kees Brinkman, Joop E. Arends, Fanny N. Lauw, Bart J. A. Rijnders, Arne van Eeden, Marianne Martinello, Gail V. Matthews, Janke Schinkel, and Maria Prins
Subjects: HCV, HCV reinfection, risk behaviour, MSM, HIV/hepatitis C virus coinfection, Medicine
Abstract: We assessed the predictive capacity of the HCV-MOSAIC risk score, originally developed for primary early HCV infection, as a screening tool for HCV reinfection in 103 men who have sex with men (MSM) with HIV using data from the MOSAIC cohort, including MSM with HIV/HCV-coinfection who became reinfected (cases, n = 27) or not (controls, n = 76) during follow-up. The overall predictive capacity of the score was assessed using the area under the receiver operating characteristic (AUROC) curve. The effects of covariates on the receiver operating characteristic (ROC) curve were assessed using parametric ROC regression. The score cut-off validated for primary early infection (≥2.0) was used, from which the sensitivity and specificity were calculated. The AUROC was 0.74 (95% confidence interval (CI) = 0.63–0.84). Group sex significantly increased the predictive capacity. Using the validated cut-off, sensitivity was 70.4% (95%CI = 49.8–86.2%) and specificity was 59.2% (95%CI: 47.3–70.4%). External validation from a cohort of 25 cases and 111 controls, all MSM with HIV, resulted in a sensitivity of 44.0% (95%CI = 24.4–65.1) and specificity of 71.2% (95%CI = 61.8–79.4). The HCV-MOSAIC risk score may be useful for identifying individuals at risk of HCV reinfection. In sexual health or HIV-care settings, this score could help guide HCV-RNA testing in MSM with a prior HCV infection.
Published: 2023
Full Text: View/download PDF

25. Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales

Author: Syed Hassan Bin Usman Shah, Maryam Alavi, Behzad Hajarizadeh, Gail V. Matthews, Marianne Martinello, Mark Danta, Janaki Amin, Matthew G. Law, Jacob George, Heather Valerio, and Gregory J. Dore
Subjects: DC, HCC, hepatitis B, late HBV notification, liver disease, liver mortality, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract: Background & Aims: Population-level trends and factors associated with HBV-related decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver-related mortality are crucial to evaluate the impacts of therapeutic interventions. Methods: Trends in HBV-DC and -HCC diagnoses and liver-related mortality in New South Wales, Australia, were determined through linkage of HBV notifications (1993-2017) to hospital admissions (2001-2018), mortality (1993-2018), and cancer registry (1994-2014) databases. Late HBV notification was defined as notification at or within 2 years of a DC or HCC diagnosis. Cox proportional-hazards regression and multivariable logistic regression analyses were performed to evaluate associated factors. Results: Among 60,660 people with a HBV notification, 1,276 (2.0%) DC and 1,087 (1.8%) HCC diagnoses, and 1,219 (2.0%) liver-related deaths were documented. Since the early 2000s, the number of DC and HCC diagnoses increased; however, age-standardised incidence decreased from 2.64 and 1.95 in 2003 to 1.14 and 1.09 per 1,000 person-years in 2017, respectively. Similarly, age-standardised liver mortality decreased from 2.60 in 2003 to 1.14 per 1,000 person-years in 2017. Among people with DC and HCC diagnoses, late HBV notification declined from 41% and 40% between 2001-2009 to 29% and 25% in 2010-2018, respectively. Predictors of DC diagnosis included older age (birth
Published: 2022
Full Text: View/download PDF

26. Patterns and correlates of hepatitis C virus phylogenetic clustering among people living with HIV in Australia in the direct‐acting antiviral era: A molecular epidemiology study among participants in the CEASE cohort

Author: Sofia R. Bartlett, Andrey Verich, Joanne Carson, Samira Hosseini‐Hooshyar, Phillip Read, David Baker, Jeffrey J. Post, Robert Finlayson, Mark Bloch, Joseph S. Doyle, David Shaw, Margaret Hellard, Maria Martinez, Philippa Marks, Gregory J. Dore, Gail V. Matthews, Tanya Applegate, and Marianne Martinello
Subjects: gay and bisexual men (GBM), hepatitis C, HIV, molecular sequencing, phylogenetic analysis, Medicine
Abstract: Abstract Background and Aims In moving towards the elimination of hepatitis C virus (HCV) infection among people living with HIV, understanding HCV transmission patterns may provide insights to guide and evaluate interventions. In this study, we evaluated patterns of, and factors associated with HCV phylogenetic clustering among people living with HIV/HCV co‐infection in Australia in the direct‐acting antiviral era. Methods HCV RNA was extracted from dried blood spot (DBS) samples collected between 2014 and 2018 in the CEASE cohort study. The HCV Core‐E2 region was amplified by a polymerase chain reaction and Sanger sequenced. Maximum likelihood phylogenetic trees (1000 bootstrap replicates) were used to identify patterns of clustering (3% genetic distance threshold). Mixed‐effects logistic regression was used to determine correlates of phylogenetic clustering. Factors assessed were sexual risk behavior, education, injecting drug use, housing, employment, HIV viral load, age, sex, and sexuality. Results Phylogenetic trees were reconstructed for HCV subtype 1a (n = 139) and 3a (n = 63) sequences, with 29% (58/202) in a pair or cluster. Overall (n = 202), phylogenetic clustering was positively associated with younger age (under 40; adjusted odds ratio [aOR] 2.52, 95% confidence interval [CI] 1.20–5.29), and among gay and bisexual men (n = 168), was positively associated with younger age (aOR 2.61, 95% CI 1.10–6.19), higher education (aOR 2.58, 95% CI 1.09–6.13), and reporting high‐risk sexual behavior (aOR 3.94, 95% CI 1.31–11.84). During follow‐up, five reinfections were observed, but none were in phylogenetic clusters. Conclusion This study found a high proportion of phylogenetic relatedness, predominantly among younger people and gay and bisexual men reporting high‐risk sexual behavior. Despite this, few reinfections were observed, and reinfections demonstrated little relationship with known clusters. These findings highlight the importance of rapid HCV treatment initiation, together with monitoring of the phylogeny.
Published: 2022
Full Text: View/download PDF

27. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia

Author: Valerio, Heather, Alavi, Maryam, Law, Matthew, Tillakeratne, Shane, Amin, Janaki, Janjua, Naveed Z., Krajden, Mel, George, Jacob, Matthews, Gail V., Hajarizadeh, Behzad, Degenhardt, Louisa, Grebely, Jason, and Dore, Gregory J.
Published: 2021
Full Text: View/download PDF

28. Modeling based response guided therapy in subjects with recent hepatitis C infection

Author: Gorstein, Evan, Martinello, Marianne, Churkin, Alexander, Dasgupta, Swikriti, Walsh, Kevin, Applegate, Tanya L., Yardeni, David, Etzion, Ohad, Uprichard, Susan L., Barash, Danny, Cotler, Scott J., Matthews, Gail V., and Dahari, Harel
Published: 2020
Full Text: View/download PDF

29. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Author: Dore, Gregory J., Feld, Jordan J., Thompson, Alex, Martinello, Marianne, Muir, Andrew J., Agarwal, Kosh, Müllhaupt, Beat, Wedemeyer, Heiner, Lacombe, Karine, Matthews, Gail V., Schultz, Michael, Klein, Marina, Hezode, Christophe, Mercade, Gerard Estivill, Kho, Danny, Petoumenos, Kathy, Marks, Philippa, Tatsch, Fernando, Dos Santos, Ana Gabriela Pires, and Gane, Ed
Published: 2020
Full Text: View/download PDF

30. One-third of people who inject drugs are at risk of incomplete treatment for Staphylococcus aureus bacteraemia: a retrospective medical record review

Author: Liam S. Acheson, Krista J. Siefried, Brendan Clifford, Emily Murray, Maureen Steele, Liesa Clague, Victoria Malone, Darren M. Roberts, Lisa-Jayne Ferguson, Gail V. Matthews, and Nadine Ezard
Subjects: Staphylococcus aureus bacteraemia, People who inject drugs, Healthcare services, Infectious diseases, Drug dependence, Infectious and parasitic diseases, RC109-216
Abstract: ABSTRACT: Staphylococcus aureus bacteraemia (SAB) is often a complication of injecting drug use, and is associated with high morbidity and mortality. This article reports the first audit of inpatient parenteral treatment of SAB completion among people who inject drugs (PWID) in Australia. Of 198 patients admitted with SAB, 106 were analysed. Twelve PWID had an inpatient stay
Published: 2021
Full Text: View/download PDF

31. A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections

Author: Olmstead, Andrea D., Montoya, Vincent, Chui, Celia K., Dong, Winnie, Joy, Jeffrey B., Tai, Vera, Poon, Art F.Y., Nguyen, Thuy, Brumme, Chanson J., Martinello, Marianne, Matthews, Gail V., Richard Harrigan, P., Dore, Gregory J., Applegate, Tanya L., Grebely, Jason, and Howe, Anita Y.M.
Published: 2019
Full Text: View/download PDF

32. Factors associated with hepatitis C treatment uptake among females of childbearing age in New South Wales, Australia: A population‐based study.

Author: Valerio, Heather, Alavi, Maryam, Marshall, Alison D., Hajarizadeh, Behzad, Amin, Janaki, Law, Matthew, Tillakeratne, Shane, George, Jacob, Degenhardt, Louisa, Grebely, Jason, Matthews, Gail V., and Dore, Gregory J.
Subjects: CHILDBEARING age, HEPATITIS C, INDIGENOUS Australians, DRUG addiction, HEPATITIS C virus
Abstract: Introduction: Females of childbearing age with hepatitis C virus (HCV) face increased marginalisation with intersecting, sex‐specific barriers to direct acting antiviral (DAA) therapy. We assessed the factors associated with uptake of DAA therapy among females of childbearing age, including those with evidence of recent drug dependence. Methods: HCV notifications in New South Wales, Australia (1995–2017) were linked to opioid agonist therapy (OAT), hospitalisations, incarcerations, perinatal, HIV notifications, deaths and prescription databases. Recent drug dependence was defined as hospitalisation due to injectable drugs or receipt of OAT occurring in the DAA era (2016–2018). Logistic regression was used to analyse factors associated with DAA uptake among females of childbearing age (18–44), including those with recent drug dependence. Results: Among 57,467 people with evidence of chronic HCV in the DAA era (2016–2018), 20,161 (35%) were female, including 33% (n = 6563/20,161) of childbearing age (18–44). Among all females of childbearing age (n = 6563) and those with evidence of recent drug dependence (n = 2278/6563, 35%), DAA uptake was lower among those who had given birth in the DAA era (vs. no birth record, all females of childbearing age; aOR: 0.74, 95% CI 0.61, 0.89; those with recent drug dependence; aOR 0.69, 95% CI 0.51, 0.93) and Aboriginal and Torres Strait Islander peoples (all females of childbearing age; aOR 0.81, 95% CI 0.71, 0.93; those with recent drug dependence aOR 0.75, 95% CI 0.62, 0.90). Conclusion: Females of childbearing age should be considered a key population for DAA therapy. Enhancing antenatal and postnatal HCV care may be critical in the pursuit towards elimination. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

33. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants.

Author: Fiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, David Ross Darley, Deepti Pilli, Daniele Vitale, Vera Merheb, Fiona X Z Lee, Philip Cunningham, Gregory J Walker, Christina Fichter, David A Brown, William D Rawlinson, Sonia R Isaacs, Vennila Mathivanan, Markus Hoffmann, Stefan Pöhlman, Ohan Mazigi, Daniel Christ, Dominic E Dwyer, Rebecca J Rockett, Vitali Sintchenko, Veronica C Hoad, David O Irving, Gregory J Dore, Iain B Gosbell, Anthony D Kelleher, Gail V Matthews, Fabienne Brilot, and Stuart G Turville
Subjects: Medicine
Abstract: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response and its evasion by emerging viral variants and variant of concern (VOC) are unknown, but critical to understand reinfection risk and breakthrough infection following vaccination. Antibody immunoreactivity against SARS-CoV-2 antigens and Spike variants, inhibition of Spike-driven virus-cell fusion, and infectious SARS-CoV-2 neutralization were characterized in 807 serial samples from 233 reverse transcription polymerase chain reaction (RT-PCR)-confirmed Coronavirus Disease 2019 (COVID-19) individuals with detailed demographics and followed up to 7 months. A broad and sustained polyantigenic immunoreactivity against SARS-CoV-2 Spike, Membrane, and Nucleocapsid proteins, along with high viral neutralization, was associated with COVID-19 severity. A subgroup of "high responders" maintained high neutralizing responses over time, representing ideal convalescent plasma donors. Antibodies generated against SARS-CoV-2 during the first COVID-19 wave had reduced immunoreactivity and neutralization potency to emerging Spike variants and VOC. Accurate monitoring of SARS-CoV-2 antibody responses would be essential for selection of optimal responders and vaccine monitoring and design.
Published: 2021
Full Text: View/download PDF

34. Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy

Author: Grebely, Jason, Conway, Brian, Cunningham, Evan B., Fraser, Chris, Moriggia, Alberto, Gane, Ed, Stedman, Catherine, Cooper, Curtis, Castro, Erika, Schmid, Patrick, Petoumenos, Kathy, Hajarizadeh, Behzad, Marks, Phillipa, Erratt, Amanda, Dalgard, Olav, Lacombe, Karine, Feld, Jordan J., Bruneau, Julie, Daulouede, Jean-Pierre, Powis, Jeff, Bruggmann, Philip, Matthews, Gail V., Kronborg, Ian, Shaw, David, Dunlop, Adrian, Hellard, Margaret, Applegate, Tanya L., Crawford, Sione, and Dore, Gregory J
Published: 2018
Full Text: View/download PDF

35. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study

Author: Cunningham, Evan B., Amin, Janaki, Feld, Jordan J., Bruneau, Julie, Dalgard, Olav, Powis, Jeff, Hellard, Margaret, Cooper, Curtis, Read, Phillip, Conway, Brian, Dunlop, Adrian J., Norton, Briana, Litwin, Alain H., Hajarizadeh, Behzad, Thurnheer, Maria Christine, Dillon, John F., Weltman, Martin, Shaw, David, Bruggmann, Philip, Gane, Edward, Fraser, Chris, Marks, Philippa, Applegate, Tanya L., Quiene, Sophie, Siriragavan, Sharmila, Matthews, Gail V., Dore, Gregory J., and Grebely, Jason
Published: 2018
Full Text: View/download PDF

36. Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs

Author: Martinello, Marianne, Dore, Gregory J., Matthews, Gail V., and Grebely, Jason
Published: 2018
Full Text: View/download PDF

37. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

Author: Grebely, Jason, Dalgard, Olav, Conway, Brian, Cunningham, Evan B, Bruggmann, Philip, Hajarizadeh, Behzad, Amin, Janaki, Bruneau, Julie, Hellard, Margaret, Litwin, Alain H, Marks, Philippa, Quiene, Sophie, Siriragavan, Sharmila, Applegate, Tanya L, Swan, Tracy, Byrne, Jude, Lacalamita, Melanie, Dunlop, Adrian, Matthews, Gail V, Powis, Jeff, Shaw, David, Thurnheer, Maria Christine, Weltman, Martin, Kronborg, Ian, Cooper, Curtis, Feld, Jordan J, Fraser, Chris, Dillon, John F, Read, Phillip, Gane, Ed, and Dore, Gregory J
Published: 2018
Full Text: View/download PDF

38. Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

Author: Jason Grebely, Phillip Read, Evan B. Cunningham, Martin Weltman, Gail V. Matthews, Adrian Dunlop, Mark Montebello, Marianne Martinello, Rosie Gilliver, Philippa Marks, Tanya L. Applegate, Gregory J. Dore, and the DARLO‐C Study Group
Subjects: DAA, drug use, hepatitis C, injecting drug users, PWID, treatment, Medicine
Abstract: Abstract Background and Aims Direct‐acting antiviral therapy for hepatitis C virus (HCV) is effective, but few prospective studies among people with ongoing injecting drug use exist. This study evaluated the efficacy of elbasvir/grazoprevir in people with HCV genotype 1/4 (G1/4) infection and recent injecting drug use. An exploratory aim evaluated the feasibility of fingerstick point‐of‐care HCV RNA testing prior to and following treatment. Methods DARLO‐C (ClinicalTrials.gov: NCT02940691) is an open‐label phase 4 trial. Participants were recruited between May 2017 and March 2018 from two drug treatment clinics, two hospital clinics, and one community clinic in Australia. Inclusion criteria included recent injection drug use (previous 6 months) and HCV G1/4 infection. Exclusion criteria included prior HCV treatment and decompensated liver disease. Participants received elbasvir/grazoprevir once‐daily for 12 weeks. The primary endpoint was undetectable HCV RNA 12 weeks post‐treatment (SVR). Fingerstick whole‐blood samples were tested using the Xpert HCV Viral Load Fingerstick (Xpert HCV VL Fingerstick) assay and compared to the Aptima HCV Quant Dx Assay on plasma samples. Results Of a planned 150 participants, 32 were enrolled due to slower than anticipated recruitment [median age 46 years, 10 (31%) female, 29 (91%) G1a]. Eighteen (56%) were receiving opioid agonist therapy and 29 (91%) injected in the previous month. Twenty‐six (81%) of 32 completed treatment (lost to follow‐up, n = 5; incarceration, n = 1). There were no virological failures. Twenty‐four (75%, 95% CI 59%‐91%) of 32 achieved SVR. Two participants who completed treatment did not have SVR (loss to follow‐up, n = 1; refused test, n = 1). Among paired samples (n = 36), sensitivity of the Xpert HCV VL Fingerstick assay for HCV RNA detection was 100.0% (95% CI 75.3%‐100.0%) and specificity was 95.7% (95% CI 78.1%‐99.9%). Conclusion Elbasvir/grazoprevir is effective among people with HCV G1 with recent injecting drug use. Implementation of point‐of‐care HCV RNA testing was feasible, but the high error rate requires investigation.
Published: 2020
Full Text: View/download PDF

39. Risk of Primary Incident Hepatitis C Infection Following Bacterial Sexually Transmissible Infections Among Gay and Bisexual Men in Australia From 2016 to 2020.

Author: Harney, Brendan L, Sacks-Davis, Rachel, Agius, Paul, Santen, Daniela K van, Traeger, Michael W, Wilkinson, Anna L, Asselin, Jason, Fairley, Christopher K, Roth, Norman, Bloch, Mark, Matthews, Gail V, Donovan, Basil, Guy, Rebecca, Stoové, Mark, Hellard, Margaret E, and Doyle, Joseph S
Subjects: SEXUALLY transmitted diseases, BISEXUAL men, HEPATITIS C, GAY men, BACTERIAL diseases, SYPHILIS, GONORRHEA
Abstract: Background In Australia, the incidence of hepatitis C virus (HCV) has declined among gay and bisexual men (GBM) with human immunodeficiency virus (HIV) since 2015 and is low among GBM using HIV preexposure prophylaxis (PrEP). However, ongoing HCV testing and treatment remains necessary to sustain this. To assess the potential utility of sexually transmissible infections (STIs) to inform HCV testing among GBM with HIV and GBM using PrEP, we examined the association between bacterial STI diagnoses and subsequent primary HCV infection. Methods Data were from a national network of 46 clinics participating in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance. GBM included had ≥1 HCV antibody negative test result and ≥1 subsequent HCV antibody and/or RNA test. Discrete time survival analysis was used to estimate the association between a positive syphilis, rectal chlamydia, and rectal gonorrhea diagnosis in the previous 2 years and a primary HCV diagnosis, defined as a positive HCV antibody or RNA test result. Results Among 6529 GBM with HIV, 92 (1.4%) had an incident HCV infection. A prior positive syphilis diagnosis was associated with an incident HCV diagnosis (adjusted hazard ratio, 1.99 [95% confidence interval, 1.11–3.58]). Among 13 061 GBM prescribed PrEP, 48 (0.4%) had an incident HCV diagnosis. Prior rectal chlamydia (adjusted hazard ratio, 2.75 [95% confidence interval, 1.42–5.32]) and rectal gonorrhea (2.54 [1.28–5.05]) diagnoses were associated with incident HCV. Conclusions Diagnoses of bacterial STIs in the past 2 years was associated with HCV incidence. These findings suggest that STIs might be useful for informing HCV testing decisions and guidelines for GBM with HIV and GBM using PrEP. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

40. Hepatitis C virus reinfection incidence among gay and bisexual men with HIV in Australia from 2016 to 2020.

Author: Harney, Brendan L., Sacks‐Davis, Rachel, van Santen, Daniela K., Traeger, Michael W., Wilkinson, Anna L., Asselin, Jason, Fairley, Christopher K., Roth, Norman, Bloch, Mark, Matthews, Gail V., Donovan, Basil, Guy, Rebecca, Stoové, Mark, Hellard, Margaret E., and Doyle, Joseph S.
Subjects: HEPATITIS C virus, BISEXUAL men, GAY men, REINFECTION, SEXUALLY transmitted diseases
Abstract: Background: There is some concern that hepatitis C virus (HCV) reinfection might impact HCV micro‐elimination efforts among gay and bisexual men (GBM) with HIV. However, there is a limited understanding of reinfection incidence in the context of unrestricted government‐funded HCV treatment. We aimed to estimate HCV reinfection incidence among GBM with HIV in Australia from 2016 to 2020. Methods: Data were from 39 clinics participating in ACCESS, a sentinel surveillance network for blood borne viruses and sexually transmissible infections across Australia. GBM with HIV who had evidence of treatment or spontaneous clearance with at least one positive HCV RNA test, a subsequent negative HCV RNA test, and at least one additional HCV RNA test between 1st January 2016 and 31st December 2020 were eligible for inclusion. A new HCV RNA positive test and/or detectable viral load was defined as a reinfection. Generalised linear modelling was used to examine trends in reinfection. Results: Among 12 213 GBM with HIV who had at least one HCV test, 540 were included in the reinfection incidence analysis, of whom 38 (7%) had evidence of reinfection during the observation period. Over 1124 person‐years of follow‐up, the overall rate of reinfection was 3.4/100PY (95% CI 2.5–4.6). HCV reinfection incidence declined on average 30% per calendar year (Incidence Rate Ratio 0.70, 95% CI 0.54–0.91). Conclusion: HCV reinfection incidence has declined among GBM with HIV in Australia since government‐funded unrestricted DAAs were made available. Ongoing HCV RNA testing following cure and prompt treatment for anyone newly diagnosed is warranted to sustain this. [ABSTRACT FROM AUTHOR]
Published: 2024
Full Text: View/download PDF

41. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection—Lessons for Functional HBV Cure?

Author: Audsley, Jennifer, Avihingsanon, Anchalee, Littlejohn, Margaret, Bowden, Scott, Matthews, Gail V., Fairley, Christopher K., Lewin, Sharon R., and Sasadeusz, Joe
Published: 2020
Full Text: View/download PDF

42. Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000‐2014)

Author: Reem Waziry, Jason Grebely, Janaki Amin, Maryam Alavi, Behzad Hajarizadeh, Jacob George, Gail V. Matthews, Matthew Law, and Gregory J. Dore
Subjects: Diseases of the digestive system. Gastroenterology, RC799-869
Abstract: We assessed trends in HCC survival in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales, Australia. Data on HBV (n = 54,399) and HCV (n = 96,908) notifications (1993‐2012) were linked to a hospitalization database (July 2000‐June 2014), the New South Wales Cancer Registry, and the New South Wales Death Registry. A total of 725 (1.3%) first HBV‐hepatocellular carcinoma (HCC) and 1,309 (1.4%) first HCV‐HCC hospitalizations were included. Death occurred in 60.4% of HBV‐HCC and 69.6% of HCV‐HCC patients. Median survival following first HBV‐HCC hospitalization improved from 0.6 years (95% confidence interval [CI] 0.39‐1.28) in 2000‐2004 to 2.8 years (1.54‐5.54) in 2010‐2014. Median survival following first HCV‐HCC hospitalization was 0.8 years (0.45‐1.33) in 2000‐2004 and 0.9 (0.67‐1.18) in 2010‐2014. One‐year HBV‐HCC survival in 2010‐2014 compared to 2000‐2004 improved for those with (94% versus 81%) and without (42% versus 33%) potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation). Factors associated with improved survival following HBV‐HCC were later study period (hazard ratio [HR] = 0.74; 95% CI, 0.57‐0.97) and potentially curative procedures (liver resection, liver transplantation, and radiofrequency ablation) (HR = 0.23; 95% CI, 0.17‐0.29), while male gender (HR = 1.37; 95% CI, 1.03‐1.82), human immunodeficiency virus coinfection (HR = 3.06; 95% CI, 1.36‐6.88), and Charlson Comorbidity Index ≥3 (HR = 1.81; 95% CI, 1.35‐2.40) were associated with reduced survival. Factors associated with improved survival following HCC‐HCV were Asia‐Pacific country of birth (HR = 0.68; 95% CI, 0.55‐0.84) and potentially curative procedures (HR = 0.21; 95% CI, 0.17‐0.25), while age (HR = 1.01; 95% CI, 1.01‐1.02), rural place of residence (HR = 1.46; 95% CI, 1.22‐1.74), and human immunodeficiency virus coinfection (HR = 2.71; 95% CI, 1.19‐6.15) were associated with reduced survival. Conclusion: All‐cause survival following HBV‐HCC has improved considerably, suggesting an impact of more effective antiviral therapy and earlier HCC diagnosis; in contrast, all‐cause survival for HCV‐HCC is unchanged. (Hepatology Communications 2017;1:736–747)
Published: 2017
Full Text: View/download PDF

43. Hepatitis C treatment as prevention: evidence, feasibility, and challenges

Author: Hajarizadeh, Behzad, Grebely, Jason, Martinello, Marianne, Matthews, Gail V, Lloyd, Andrew R, and Dore, Gregory J
Published: 2016
Full Text: View/download PDF

44. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014)

Author: Waziry, Reem, Grebely, Jason, Amin, Janaki, Alavi, Maryam, Hajarizadeh, Behzad, George, Jacob, Matthews, Gail V., Law, Matthew, and Dore, Gregory J.
Published: 2016
Full Text: View/download PDF

45. HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection

Author: Bartlett, Sofia R., Jacka, Brendan, Bull, Rowena A., Luciani, Fabio, Matthews, Gail V., Lamoury, Francois M.J., Hellard, Margaret E., Hajarizadeh, Behzad, Teutsch, Suzy, White, Bethany, Maher, Lisa, Dore, Gregory J., Lloyd, Andrew R., Grebely, Jason, and Applegate, Tanya L.
Published: 2016
Full Text: View/download PDF

46. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C

Author: Alavi, Maryam, Spelman, Tim, Matthews, Gail V., Haber, Paul S., Day, Carolyn, van Beek, Ingrid, Walsh, Nick, Yeung, Barbara, Bruneau, Julie, Petoumenos, Kathy, Dolan, Kate, Kaldor, John M., Dore, Gregory J., Hellard, Margaret, and Grebely, Jason
Published: 2015
Full Text: View/download PDF

47. Enhancing the detection and management of acute hepatitis C virus infection

Author: Martinello, Marianne and Matthews, Gail V.
Published: 2015
Full Text: View/download PDF

48. Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types

Author: Lamoury, François M.J., Bartlett, Sofia, Jacka, Brendan, Hajarizadeh, Behzad, Grebely, Jason, Matthews, Gail V., Dore, Gregory J., and Applegate, Tanya L.
Published: 2015
Full Text: View/download PDF

49. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial

Author: Rockstroh, Jürgen K, Nelson, Mark, Katlama, Christine, Lalezari, Jay, Mallolas, Josep, Bloch, Mark, Matthews, Gail V, Saag, Michael S, Zamor, Philippe J, Orkin, Chloe, Gress, Jacqueline, Klopfer, Stephanie, Shaughnessy, Melissa, Wahl, Janice, Nguyen, Bach-Yen T, Barr, Eliav, Platt, Heather L, Robertson, Michael N, and Sulkowski, Mark
Published: 2015
Full Text: View/download PDF

50. Retreatment for hepatitis C virus direct‐acting antiviral therapy virological failure in primary and tertiary settings: The <scp>REACH‐C</scp> cohort

Author: Joanne M, Carson, Behzad, Hajarizadeh, Josh, Hanson, James, O'Beirne, David, Iser, Phillip, Read, Anne, Balcomb, Jane, Davies, Joseph S, Doyle, Jasmine, Yee, Marianne, Martinello, Philippa, Marks, Gail V, Matthews, and Gregory J, Dore
Subjects: Infectious Diseases, Hepatology, Virology
Abstract: Virological failure occurs in a small proportion of people treated for hepatitis C virus (HCV) with direct-acting antiviral (DAA) therapies. This study assessed retreatment for virological failure in a large real-world cohort. REACH-C is an Australian observational study (n=10843) evaluating treatment outcomes of sequential DAA initiations across 33 health services between March 2016 to June 2019. Virological failure retreatment data were collected until October 2020. Of 408 people with virological failure (81% male; median age 53; 38% cirrhosis; 56% genotype 3), 213 (54%) were retreated once; 15 were retreated twice. A range of genotype specific and pangenotypic DAAs were used to retreat virological failure in primary (n=56) and tertiary (n=157) settings. Following sofosbuvir/velpatasvir/voxilaprevir availability in 2019, the proportion retreated in primary care increased from 21% to 40% and median time to retreatment initiation declined from 294 to 152 days. Per-protocol (PP) sustained virological response (SVR12) was similar for people retreated in primary and tertiary settings (80% vs 81%; p=1.000). In regression analysis, sofosbuvir/velpatasvir/voxilaprevir (vs. other regimens) significantly decreased likelihood of second virological failure (PP SVR12 88% vs. 77%; adjusted odds ratio [AOR] 0.29; 95%CI 0.11-0.81); cirrhosis increased likelihood (PP SVR12 69% vs. 91%; AOR 4.26; 95%CI 1.64-11.09). Indigenous Australians had lower likelihood of retreatment initiation (AOR 0.36; 95%CI 0.15-0.81). Treatment setting and prescriber type were not associated with retreatment initiation or outcome. Virological failure can be effectively retreated in primary care. Expanded access to simplified retreatment regimens through decentralised models may increase retreatment uptake and reduce HCV-related mortality.
Published: 2022
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

303 results on '"Matthews, Gail V '

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources